drugset / Trial / NCT04051957
Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury
Phase 2
Terminated
9 enrolled
The University of Texas Health Science Center, Houston
National Kidney Foundation, United States · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to test the hypothesis that isosorbide mononitrate prevents deterioration of renal function in patients receiving anti-angiogenic therapies that target vascular endothelial growth factor (VEGF).
Timeline
- Start
- 2019-09-26
- Primary completion
- 2021-02-12
- Completion
- 2021-02-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Isosorbide Mononitrate | Other / unclassified | 120 mg | — |